Infosys Buys US Tech Firms for $560M to Bolster Healthcare

Infosys has acquired U.S.-based Optimum Healthcare IT for approximately $465 million and Stratus for up to $95 million. This combined $560 million investment aims to expand Infosys's expertise in the healthcare and insurance technology sectors. The deals are expected to close in the first quarter of fiscal year 2027. This strategic move occurs as Infosys's stock has declined roughly 21% year-over-year and 26.59% in the past 12 months. The broader Nifty IT index is down 25% in 2026. While Nomura reiterated a 'Buy' rating with a target price suggesting 42% upside, analysts generally hold a more cautious view.

Analysts Mixed on Impact as Sector Faces Headwinds

The Indian IT sector is navigating a challenging environment with slower revenue growth and concerns about AI disrupting business models. For the first quarter of fiscal year 2026, tier-1 IT firms like Infosys are expected to see slow revenue growth. Analysts view these acquisitions as earnings-neutral to slightly dilutive, potentially adding about 1.2% to revenue by FY27 and contributing around 2-2.5% inorganic growth. Historically, Infosys shares have sometimes dipped after acquisition announcements, dropping an average of 2.6% the next trading day. Infosys's P/E ratio of about 17-18 is below its 10-year median, suggesting possible undervaluation, while the sector’s P/E is 21.1. Competitors like TCS and HCL Technologies trade at higher multiples, showing different market views on growth potential. Integrating Optimum and Stratus will be key to achieving benefits, especially as Infosys plans to use its Topaz AI and Cobalt cloud platforms to set itself apart from rivals. Other firms like JM Financial maintain 'Buy' ratings but note a changing risk-reward balance.

Execution Risks and Margin Pressure Loom

Significant risks remain for these acquisitions. A primary concern is successfully executing the integration of two different U.S. companies, particularly in complex, regulated sectors like healthcare and insurance. Analysts, including those at Morgan Stanley, maintain a more cautious rating, expecting earnings to be neutral or diluted. The projected revenue contribution must be considered against slower integration and client uptake, which could hurt profit margins. The broader IT market faces tough demand, with clients scrutinizing spending and focusing on AI skills, possibly slowing down new deals. Competition is also intensifying. While Infosys's market value of about $53-54 billion gives it scale, its recent stock underperformance suggests the market is waiting for clear results from these acquisitions. The ability to manage costs and use overseas resources to boost profits will be vital, especially since the deals may face short-term margin pressure.

Outlook Depends on Integration and Market Conditions

Infosys expects acceleration in its financial services and energy, utilities, resources, and services (EURS) divisions in FY27, backed by strong deal wins and AI partnerships. Management has forecast FY26 revenue growth of 3.0-3.5%. Analyst consensus is mostly 'Hold,' with price targets suggesting a limited upside of about 30-38%. These acquisitions aim to boost Infosys's position and revenue, but success depends on smooth integration, stable IT spending, and adapting to changing client needs and AI shifts.